Identifying Biomarkers and Effective Therapies for ALS with Alon Ben-Noon NeuroSense Therapeutics

Alon Ben-Noon is the Co-Founder and CEO of NeuroSense Therapeutics, which is working on ALS therapy and other neurodegenerative diseases like Parkinson's and Alzheimer's. They are working on a disease-modifying drug PrimeC and have identified a large set of biomarkers that are related to ALS progression and the mechanisms of PrimeC. Alon explains, "Our lead candidate is called PrimeC. It's a novel formulation that consists of two FDA-approved drugs not related to ALS. We found that when these drugs are combined together in unique doses, they had the quality to treat ALS and tackle ALS in several forms. This formulation aims to maximize the synergism that we found to have between these compounds and as I mentioned, to tackle multiple targets in order to eventually create a clinical benefit for the patients." "We are advancing with identifying biomarkers and progressing there very nicely. We identified a large set of biomarkers that relates both to the disease progression and to the mechanisms of PrimeC. We work on neuron-derived exosomes, and when we first characterize the set of biomarkers that are relevant for us, we also explored how PrimeC, our lead candidate, can create a change in these biomarkers." @NeuroSenseT #NeuroSense #Neurodegenerative #PrimeC #Biotech #RareDiseases #CNS #ALS #Alzheirmers #AD #Parkinsons #PD #Biomarkers NeuroSense-TX.com Download the transcript here